Dyne Therapeutics (NASDAQ:DYN) Shares Gap Down on Insider Selling

Dyne Therapeutics, Inc. (NASDAQ:DYN)’s share price gapped down prior to trading on Wednesday following insider selling activity. The stock had previously closed at $32.63, but opened at $31.63. Dyne Therapeutics shares last traded at $31.07, with a volume of 1,011,286 shares.

Specifically, insider Oxana Beskrovnaya sold 30,426 shares of the company’s stock in a transaction on Monday, May 20th. The stock was sold at an average price of $32.96, for a total value of $1,002,840.96. Following the completion of the transaction, the insider now directly owns 149,647 shares in the company, valued at $4,932,365.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Dyne Therapeutics news, insider Oxana Beskrovnaya sold 30,426 shares of the company’s stock in a transaction dated Monday, May 20th. The stock was sold at an average price of $32.96, for a total transaction of $1,002,840.96. Following the completion of the sale, the insider now directly owns 149,647 shares in the company, valued at $4,932,365.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Jason P. Rhodes sold 248,219 shares of the company’s stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $23.72, for a total value of $5,887,754.68. Following the sale, the director now owns 903,527 shares of the company’s stock, valued at $21,431,660.44. The disclosure for this sale can be found here. Insiders sold a total of 934,841 shares of company stock valued at $23,103,069 over the last three months. 20.77% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on DYN shares. Jefferies Financial Group increased their price target on Dyne Therapeutics from $36.00 to $42.00 and gave the company a “buy” rating in a report on Monday. Piper Sandler raised their target price on Dyne Therapeutics from $27.00 to $29.00 and gave the company an “overweight” rating in a research report on Wednesday, March 6th. Chardan Capital raised their price objective on Dyne Therapeutics from $31.00 to $42.00 and gave the stock a “buy” rating in a research note on Tuesday. Morgan Stanley started coverage on Dyne Therapeutics in a research note on Tuesday, April 30th. They set an “overweight” rating and a $40.00 price objective for the company. Finally, Oppenheimer reissued an “outperform” rating and set a $47.00 price objective on shares of Dyne Therapeutics in a research note on Monday, May 6th. One analyst has rated the stock with a sell rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $40.78.

Dyne Therapeutics Stock Performance

The business has a 50-day moving average of $27.05 and a two-hundred day moving average of $20.50.

Dyne Therapeutics (NASDAQ:DYN) last released its quarterly earnings data on Thursday, May 2nd. The company reported ($0.81) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.81). Analysts anticipate that Dyne Therapeutics, Inc. will post -3.1 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. Principal Financial Group Inc. raised its position in shares of Dyne Therapeutics by 5.9% during the 1st quarter. Principal Financial Group Inc. now owns 15,403 shares of the company’s stock valued at $437,000 after acquiring an additional 857 shares during the last quarter. Wetzel Investment Advisors Inc. acquired a new position in shares of Dyne Therapeutics in the 1st quarter valued at $28,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Dyne Therapeutics by 5.5% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 22,921 shares of the company’s stock valued at $305,000 after buying an additional 1,199 shares during the period. Ameritas Investment Partners Inc. grew its holdings in shares of Dyne Therapeutics by 28.0% in the 1st quarter. Ameritas Investment Partners Inc. now owns 5,896 shares of the company’s stock valued at $167,000 after buying an additional 1,291 shares during the period. Finally, Russell Investments Group Ltd. grew its holdings in shares of Dyne Therapeutics by 1.4% in the 1st quarter. Russell Investments Group Ltd. now owns 101,943 shares of the company’s stock valued at $2,894,000 after buying an additional 1,447 shares during the period. Institutional investors own 96.68% of the company’s stock.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.